ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Frequently asked questions
What sector does Abivax SA (2X1) operate in?
Abivax SA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Abivax SA (2X1) current stock price?
As of the latest data, Abivax SA stock price is €95.50, with a previous close of €99.10. Abivax SA lost -€3.60 in the last trading session, representing a -3.63% loss.
What is Abivax SA (2X1) current market capitalization?
Abivax SA market cap is approximately 8.33 billion.
What is Abivax SA (2X1) Earnings Per Share (EPS)?
The trailing EPS is -€4.61.
Does Abivax SA (2X1) pay dividends?
No. Abivax SA does not pay a dividend.
When is Abivax SA (2X1) next earnings report?
Abivax SA is expected to release its next earnings report on June 30, 2026.
What is Abivax SA (2X1) beta (volatility) score?
Abivax SA has a beta of -0.248, indicating lower volatility than the overall market.